Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased due to the pharmaceuticals business, including product groups in the obstetrics and gynecology field, which performed steadily, growth in key products, and the consolidation of Ha Tay Pharmaceutical Joint Stock Company as a subsidiary. Operating profit increased with the rise in revenue, while selling, general and administrative expenses increased due to higher costs associated with progress in research and development. Profit attributable to owners of the parent included a gain on sale of investment securities of ¥1,474 million, among other items.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥71,127 million (YoY +10.9%) |
| Operating profit | ¥5,834 million (YoY +9.4%) |
| Ordinary income | ¥5,665 million (YoY +10.9%) |
| Profit attributable to owners of the parent | ¥5,424 million (YoY +6.3%) |
| Net income per share | ¥191.12 |
| Operating Margin | 8.2％ |
| Equity ratio | End of the current fiscal period 62.5 ％ / End of previous period 62.6 ％ |
| Total assets | ¥112,012 million |
| Net assets | ¥76,452 million |
| Cash flows from operating activities | ¥6,303 million |
| Cash flows from investing activities | ¥-5,752 million |
| Cash flows from financing activities | ¥-818 million |
| Cash and cash equivalents at end of period | ¥10,126 million |
| Full-year earnings forecast | Net Sales ¥73,000 million (YoY +2.6%) / Operating profit ¥6,200 million (YoY +6.3%) / Ordinary income ¥6,100 million (YoY +7.7%) / Profit attributable to owners of the parent ¥4,800 million (YoY -11.5%) |
| Annual Dividend Forecast | ¥60 per share (previous fiscal year actual to next fiscal year forecast) → ¥65 per share (previous fiscal year actual to next fiscal year forecast)（+8.3%） |
| Payout ratio | 38.4% (forecast for the fiscal year ending March 2027) |
| Shareholder Return Policy | A consolidated payout ratio of approximately 30% is the guideline. From the fiscal year ending March 2027, the company will use a total payout ratio of approximately 40% as the guideline and introduce progressive dividends, excluding special dividends. |
| Segment revenue | Pharmaceuticals Business ¥58,927 million (YoY +4.0%), Animal Health Business ¥7,334 million (YoY +1.2%), Overseas Business ¥4,640 million, Other Businesses ¥225 million (YoY -5.2%) |
| Segment profit | Pharmaceuticals Business ¥7,121 million (YoY +12.1%), Animal Health Business ¥344 million (YoY +14.7%), Overseas Business ¥108 million, Other Businesses ¥-13 million |
| Depreciation and amortization | ¥2,917 million |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on disposal of fixed assets ¥96 million, Gain on sale of investment securities ¥1,474 million / Extraordinary loss Impairment Loss on Investment Securities ¥244 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 28,763,199 Shares |
| Treasury Shares at Period-End | 367,085 Shares |
| Factors Behind Changes in Business Performance | Revenue increased due to the pharmaceuticals business, including product groups in the obstetrics and gynecology field, which performed steadily, growth in key products, and the consolidation of Ha Tay Pharmaceutical Joint Stock Company as a subsidiary. Operating profit increased with the rise in revenue, while selling, general and administrative expenses increased due to higher costs associated with progress in research and development. Profit attributable to owners of the parent included a gain on sale of investment securities of ¥1,474 million, among other items. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the fiscal year under review, revenue increased on the steady performance of product groups in the obstetrics and gynecology field and other areas, growth in key products, and the consolidation of Ha Tay Pharmaceutical Joint Stock Company as a subsidiary. For the next fiscal year, the company expects contributions from an increase in the minimum drug price, growth in products in the obstetrics and gynecology field and other areas, and its overseas business. The document does not explicitly state why profit attributable to owners of the parent is expected to decline in the next fiscal year.